SUMINISTRO DEL MEDICAMENTO EXCLUSIVO: LEBRIKIZUMAB (EBGLYSS)
TED · 393946-2026Award noticeawardedNo deadline given
Buyer
NameServicio Madrileno de Salud, Hospital Universitario La Paz
CountryES
Published2026-06-09
Deadline—
Who already wins at this buyer
Firms with recorded awards from Servicio Madrileno de Salud, Hospital Universitario La Paz in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| ROCHE FARMA, S.A.U. | 2 | €2,779,646 | 2026-06-15 |
| GILEAD SCIENCES, S.L. | 2 | €898,026 | 2026-09-04 |
| BRISTOL-MYERS SQUIBB, S.A.U. | 2 | €824,543 | 2026-06-29 |
| BIOGEN SPAIN, S.L. | 1 | €2,964,125 | 2026-09-15 |
| ALEXION PHARMA SPAIN S.L.U. | 1 | €2,603,216 | 2026-09-09 |
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
SUMINISTRO DEL MEDICAMENTO EXCLUSIVO: LEBRIKIZUMAB (EBGLYSS)
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-05-28 | SUMINISTRO DEL MEDICAMENTO EXCLUSIVO: CEMIPLIMAB (LIBTAYO) | Servicio Madrileno de Salud, Hospital Universitario La Paz ES | 95% |
| 2026-06-04 | SUMINISTRO DE LEBRIKIZUMAB (EBGLYSS®) DE DISTRIBUCIÓN EXCLUSIVA DEL LABORATORIO ALMIRALL, S.A. CON DESTINO AL SERVICIO DE FARMACIA DEL HOSPITAL CLÍNICO SAN CARLOS | HOSPITAL CLINICO SAN CARLOS ES | 94% |
| 2026-05-05 | SUMINISTRO DEL MEDICAMENTO EXCLUSIVO IDECABTAGEN VICLEUCEL (ABECMA) | Servicio Madrileno de Salud, Hospital Universitario La Paz ES | 94% |
| 2026-05-29 | SUMINISTRO DE MEDICAMENTO EXCLUSIVO: SELADELPAR (LYVDELZI) | Servicio Madrileno de Salud, Hospital Universitario La Paz ES | 94% |
| 2026-05-04 | SUMINISTRO DEL MEDICAMENTO EXCLUSIVO: BLINATUMOMAB (BLINCYTO) | Servicio Madrileno de Salud, Hospital Universitario La Paz ES | 94% |
| 2026-09-09 | Suministro del medicamento exclusivo: Ravulizumab (ULTOMIRIS). | Servicio Madrileno de Salud, Hospital Universitario La Paz ES | 93% |